Malignant Mesothelioma

• EMA approval · 2026-01-16
  EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.

  EMA has authorised the marketing of Alimta (pemetrexed) for malignant mesothelioma and non-small cell lung cancer in the EU. The marketing a…

• EMA approval · 2026-01-15
  EMA Authorised: Pemetrexed Pfizer (previously Pemetrexed Hospira) (pemetrexed disodium;pemetrexed disodium hemipentahydrate) — Pfizer Europe MA EEIG

  The European Medicines Agency authorised a pemetrexed disodium product marketed as Pemetrexed Pfizer (formerly Pemetrexed Hospira) for non-s…

• EMA approval · 2025-11-21
  EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG

  The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…

• EMA approval · 2025-05-28
  EMA Authorised: Pemetrexed medac (pemetrexed) — medac Gesellschaft für klinische Spezialpräparate mbH

  EMA authorised medac's pemetrexed medicine for use in non-small cell lung cancer and malignant mesothelioma.

• EMA approval · 2025-02-12
  EMA Authorised: Pemetrexed Fresenius Kabi (pemetrexed) — Fresenius Kabi Deutschland GmbH

  The EMA authorised Pemetrexed Fresenius Kabi (pemetrexed) for use in non-small cell lung cancer and malignant mesothelioma.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS approval · 2007-03-15
  Clinical Trial Update: ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

  This clinical trial update discusses pemetrexed (ALIMTA) alone or in combination with cisplatin for malignant mesothelioma and notes marketi…